SecBot SecBot
3 ·Filed Apr 24, 2026

TNGX

Tango Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-177281
Form 3, initial insider ownership statement
Actionable Insight • Neutral

No immediate trading implications. Monitor future Form 4 filings for any actual insider buying or selling activity by Gall or other executives.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.33
T+0 close · Apr 24, 2026 · via day close
Latest settled
+6.72%
T+60 · $28.10
Vs SPY
+1.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $26.33entry
  2. T+1 · 7mo ago −4.52%α −4.03% · $25.14
  3. T+5 · 7mo ago −13.75%α −14.15% · $22.71
  4. T+20 · 6mo ago −23.89%α −28.85% · $20.04
  5. T+60 · 4mo ago +6.72%α +1.95% · $28.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Matthew Gall, CFO of Tango Therapeutics, filed a Form 3 and granted a power of attorney to Julie Fogarty to file SEC reports on his behalf, including Forms 3, 4, and 5. This is a routine compliance filing related to insider reporting obligations.

Key Facts

  • Matthew Gall, CFO of Tango Therapeutics, filed a Form 3 indicating initial beneficial ownership reporting.
  • He granted power of attorney to Julie Fogarty to file Forms 3, 4, and 5, Schedule 13D/G, and amendments on his behalf.
  • The filing was made effective as of April 24, 2026, with a report date of April 15, 2026.
  • No transaction or change in beneficial ownership was disclosed; this is an administrative filing.

Financial Impact

No financial impact, this is a procedural filing with no disclosed share transactions or ownership changes.

Risk Factors

  • None identified, this is a standard regulatory requirement for officers and directors.
  • Potential for misinterpretation as a signal, but no material information was conveyed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-177281
Document: 0001193125-26-177281-index-headers.html0001193125-26-177281
Document: 0001193125-26-177281-index.html0001193125-26-177281
Document: 0001193125-26-177281.txt0001193125-26-177281

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026